These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [99mTc(CO)3]+ and [99mTcO2]+ radiolabeled cyclic melanotropin peptides for melanoma SPECT imaging.
    Author: Zhang X, Teixeira V, Porcal W, Cabral P, Gambini JP, Fernandez M, Gallazzi F, Quinn TP.
    Journal: Curr Radiopharm; 2014; 7(1):63-74. PubMed ID: 25022516.
    Abstract:
    The melanoma targeting peptides (Ala-triazol)Ac-Re(Arg(11))CCMSH and N4-CO-Re(Arg(11))CCMSH were radiolabeled with [(99m)Tc(CO)3](+) and [(99m)TcO2](+), respectively, and examined for in vitro cell binding, in vivo biodistribution and imaging properties. The (Ala-triazol)Ac-Re(Arg(11))CCMSH and N4-CO-Re(Arg(11))CCMSH were synthesized as protected peptides on resin followed by rhenium cyclization with [(C6H5)3P]2ReOCl3 in DMF. The peptides were labeled with (99m)Tc and examined for radiochemical stability and melanoma cell binding. In vivo biodistribution and SPECT/CT imaging studies were performed in B16/F1 melanoma tumor bearing C57 mice. (99m)Tc(CO)3-(Ala-Triazol)Ac- Re(Arg(11))CCMSH and (99m)TcO2-N4-CO-Re(Arg(11))CCMSH were stable and internalized in B16/F1 melanoma cells upon binding. In vivo biodistribution studies revealed that tumor uptake of (99m)Tc(CO)3-(Ala-Triazol)Ac-Re(Arg(11))CCMSH was 6.08±1.06% ID/g and 7.05±1.48% ID/g at 2 h and 4 h post injection, respectively. Tumor uptake of (99m)TcO2-N4-CORe(Arg(11))CCMSH was 7.54±1.82% ID/g and 2.28±0.22% ID/g at 1 h and 2 h post injection, respectively. SPECT/CT imaging studies showed that tumor selective uptake of the radiolabeled peptides, which was confirmed by competitive blocking studies.
    [Abstract] [Full Text] [Related] [New Search]